← All trials
NCT05415098
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2022
- Primary completion
- Sep 30, 2024
- Completion date
- Sep 30, 2025
- First posted
- Jun 10, 2022
- Last posted
- Nov 16, 2022
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Ascentage Pharma Group Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.